These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 33474678)

  • 21. Expression of Epidermal Growth Factor Receptor Detected by Cetuximab Indicates Its Efficacy to Inhibit In Vitro and In Vivo Proliferation of Colorectal Cancer Cells.
    Shigeta K; Hayashida T; Hoshino Y; Okabayashi K; Endo T; Ishii Y; Hasegawa H; Kitagawa Y
    PLoS One; 2013; 8(6):e66302. PubMed ID: 23824671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Production and introduction of a novel immunotoxin based on engineered RNase A for inducing death to Her1-positive cell lines.
    Forouharmehr A; Nassiri M; Ghovvati Roudsari S; Javadmanesh A
    J Cell Physiol; 2020 May; 235(5):4679-4687. PubMed ID: 31663127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with
    Ohishi T; Kato Y; Kaneko MK; Ohba SI; Inoue H; Harakawa A; Kawada M
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32839411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
    Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
    Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NDRG1 enhances the sensitivity of cetuximab by modulating EGFR trafficking in colorectal cancer.
    Yang G; Huang L; Jia H; Aikemu B; Zhang S; Shao Y; Hong H; Yesseyeva G; Wang C; Li S; Sun J; Zheng M; Ma J
    Oncogene; 2021 Oct; 40(41):5993-6006. PubMed ID: 34385595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan.
    Qiu W; Zhang C; Wang S; Yu X; Wang Q; Zeng D; Du P; Ma J; Zheng Y; Pang B; Yu Y; Long F; Pang X; Sun Z
    J Immunol Res; 2019; 2019():3017360. PubMed ID: 30733972
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
    Lee HW; Son E; Lee K; Lee Y; Kim Y; Lee JC; Lim Y; Hur M; Kim D; Nam DH
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of therapeutic effectiveness of (131)I-antiEGFR-BSA-PCL in a mouse model of colorectal cancer.
    Li W; Ji YH; Li CX; Liu ZY; Li N; Fang L; Chang J; Tan J
    World J Gastroenterol; 2016 Apr; 22(14):3758-68. PubMed ID: 27076760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts.
    Sreeranganathan M; Uthaman S; Sarmento B; Mohan CG; Park IK; Jayakumar R
    Int J Nanomedicine; 2017; 12():7165-7182. PubMed ID: 29033568
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
    Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
    Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
    [No Abstract]   [Full Text] [Related]  

  • 32. RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer.
    Gbenedio OM; Bonnans C; Grun D; Wang CY; Hatch AJ; Mahoney MR; Barras D; Matli M; Miao Y; Garcia KC; Tejpar S; Delorenzi M; Venook AP; Nixon AB; Warren RS; Roose JP; Depeille P
    JCI Insight; 2019 Jun; 5(15):. PubMed ID: 31237864
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies.
    Hu XY; Wang R; Jin J; Liu XJ; Cui AL; Sun LQ; Li YP; Li Y; Wang YC; Zhen YS; Miao QF; Li ZR
    Mol Oncol; 2019 Feb; 13(2):246-263. PubMed ID: 30372581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EGFR-Targeted Immunotoxin Exerts Antitumor Effects on Esophageal Cancers by Increasing ROS Accumulation and Inducing Apoptosis via Inhibition of the Nrf2-Keap1 Pathway.
    Yang Y; Tian Z; Ding Y; Li X; Zhang Z; Yang L; Zhao F; Ren F; Guo R
    J Immunol Res; 2018; 2018():1090287. PubMed ID: 30596104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.
    Tang Z; Yuan X; Du R; Cheung SH; Zhang G; Wei J; Zhao Y; Feng Y; Peng H; Zhang Y; Du Y; Hu X; Gong W; Liu Y; Gao Y; Liu Y; Hao R; Li S; Wang S; Ji J; Zhang L; Li S; Sutton D; Wei M; Zhou C; Wang L; Luo L
    Mol Cancer Ther; 2015 Oct; 14(10):2187-97. PubMed ID: 26208524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiolabeled F(ab')
    Bellaye PS; Moreau M; Raguin O; Oudot A; Bernhard C; Vrigneaud JM; Dumont L; Vandroux D; Denat F; Cochet A; Brunotte F; Collin B
    Clin Transl Oncol; 2018 Dec; 20(12):1557-1570. PubMed ID: 29777377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of SLC1A5 sensitizes colorectal cancer to cetuximab.
    Ma H; Wu Z; Peng J; Li Y; Huang H; Liao Y; Zhou M; Sun L; Huang N; Shi M; Bin J; Liao Y; Rao J; Wang L; Liao W
    Int J Cancer; 2018 Jun; 142(12):2578-2588. PubMed ID: 29363109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro and in vivo antitumor activity of ZENECA ZD0490, a recombinant ricin A-chain immunotoxin for the treatment of colorectal cancer.
    Calvete JA; Newell DR; Wright AF; Rose MS
    Cancer Res; 1994 Sep; 54(17):4684-90. PubMed ID: 8062265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carfilzomib Promotes the Unfolded Protein Response and Apoptosis in Cetuximab-Resistant Colorectal Cancer.
    Zulkifli A; Tan FH; Areeb Z; Stuart SF; Gomez J; Paradiso L; Luwor RB
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.